These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1703836)

  • 1. [Viral safety in hemotherapy. Current aspects of hepatitis C and parvovirus B19 detection for plasma component therapy].
    Sibrowski W; Kühnl P
    Beitr Infusionsther; 1990; 26():22-6. PubMed ID: 1703836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
    Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
    Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
    Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
    Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Possibilities of virus inactivation of pooled fresh plasma with tri-n-butylphosphate (TNBP) detergents (SD procedure)].
    Gürtler L
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():77-9. PubMed ID: 8000260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area.
    Parsyan A; Addo-Yobo E; Owusu-Ofori S; Akpene H; Sarkodie F; Allain JP
    Transfusion; 2006 Sep; 46(9):1593-600. PubMed ID: 16965589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
    Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
    Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-enveloped viruses transmitted by blood and blood products.
    Robertson BH; Erdman DD
    Dev Biol (Basel); 2000; 102():29-35. PubMed ID: 10794088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated risk of transmission of hepatitis C virus by blood transfusion.
    Koerner K; Cardoso M; Dengler T; Kerowgan M; Kubanek B
    Vox Sang; 1998; 74(4):213-6. PubMed ID: 9691400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence and significance of parvovirus B19 in blood and blood products.
    Siegl G; Cassinotti P
    Biologicals; 1998 Jun; 26(2):89-94. PubMed ID: 9811511
    [No Abstract]   [Full Text] [Related]  

  • 11. [Safety of blood products and B19 parvovirus].
    Lefrère JJ; Maniez-Montreuil M; Morel P; Defer C; Laperche S
    Transfus Clin Biol; 2006 Oct; 13(4):235-41. PubMed ID: 16822687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parvovirus B19 infection: not confined to exanthema of erythema infectiosum].
    Schwarz TF; Wolff HH
    Hautarzt; 1989 Jan; 40(1):1-3. PubMed ID: 2537803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus.
    Bonvicini F; Gallinella G; Cricca M; Ambretti S; Delbarba S; Musiani M; Zerbini M
    J Med Virol; 2004 Oct; 74(2):272-6. PubMed ID: 15332276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin.
    Horowitz B; Busch M
    Transfusion; 2008 Aug; 48(8):1739-53. PubMed ID: 18466171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
    Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
    Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of perinatal transmission of rubella and parvovirus B19 in Jordanian pregnant women.
    Bdour S
    Vaccine; 2006 Apr; 24(16):3309-12. PubMed ID: 16460842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human erythrovirus B19 and blood transfusion - an update.
    Parsyan A; Candotti D
    Transfus Med; 2007 Aug; 17(4):263-78. PubMed ID: 17680952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to B19 parvovirus and an antibody defect in persistent viral infection.
    Kurtzman GJ; Cohen BJ; Field AM; Oseas R; Blaese RM; Young NS
    J Clin Invest; 1989 Oct; 84(4):1114-23. PubMed ID: 2551923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral infections transmitted by blood and its products.
    Barbara JA; Tedder RS
    Clin Haematol; 1984 Oct; 13(3):693-707. PubMed ID: 6094064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay.
    Kleinman SH; Glynn SA; Lee TH; Tobler L; Montalvo L; Todd D; Kiss JE; Shyamala V; Busch MP;
    Transfusion; 2007 Oct; 47(10):1756-64. PubMed ID: 17880600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.